Loading stock data…
Mesa Laboratories, Inc. (MLAB)
$123.74-4.04 (-3.16%)
Market ClosedLast close Sep 8
Mesa Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesa Laboratories, Inc. in the Technology sector is trading at $123.74 with a market capitalization of $583M. Wall Street consensus targets $117.50 (2 analysts), implying a -5.0% move over the next 12 months. The stock is currently near its 52-week high of $132.70, remaining 30.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -5.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $63.72M↓ | $65.13M↑ | $60.74M↑ | $59.54M↓ | $62.13M |
| Gross Profit | $42.20M↑ | $41.80M↑ | $37.33M↑ | $36.94M↓ | $38.41M |
| Operating Income | $2.75M↓ | $7.97M↑ | $4.72M↑ | $3.06M↑ | $1.47M |
| Net Income | -$4.14M↓ | $3.63M↑ | $2.48M↓ | $4.74M↑ | -$7.11M |
Peer Comparison
AAPLMSFTGOOGL
Fundamentals
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control seg...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$583.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
87.22
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.52%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.60%
Volume
Today's trading volume
147,229
Recent News
Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript
CEO Kadia highlights execution fixes and debt reduction amid SDC fulfillment challenges.
Mesa Laboratories, Inc. Q1 2027 Earnings Call Summary
Moby summary of Mesa Laboratories, Inc.'s Q1 2027 earnings call
Mesa Laboratories Inc (MLAB) (Q1 2027) Earnings Call Highlights: Margin Expansion and Debt ...
Adjusted operating income surges nearly 20% as the company returns to core organic growth and strengthens its balance sheet.
Mesa Laboratories Q1 Earnings Call Highlights
Mesa Laboratories (NASDAQ:MLAB) reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control busine
Mesa Laboratories: Priced for the Problem, Not the Platform
Mesa Laboratories is priced against a declining genomics drag, while its compliance consumable segment embedded in pharma sterilization mandates earns margins the blended multiple obscures.